275 related articles for article (PubMed ID: 20046960)
1. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
Kresowik TP; Griffith TS
Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
[TBL] [Abstract][Full Text] [Related]
2. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer.
Simons MP; Nauseef WM; Griffith TS
Immunol Res; 2007; 39(1-3):79-93. PubMed ID: 17917057
[TBL] [Abstract][Full Text] [Related]
3. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guérin (BCG) immunotherapy for urothelial carcinoma of the bladder.
Rosevear HM; Lightfoot AJ; O'Donnell MA; Griffith TS
Cancer Metastasis Rev; 2009 Dec; 28(3-4):345-53. PubMed ID: 19967427
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Kemp TJ; Ludwig AT; Earel JK; Moore JM; Vanoosten RL; Moses B; Leidal K; Nauseef WM; Griffith TS
Blood; 2005 Nov; 106(10):3474-82. PubMed ID: 16037389
[TBL] [Abstract][Full Text] [Related]
5. PMN and anti-tumor immunity--the case of bladder cancer immunotherapy.
Brincks EL; Risk MC; Griffith TS
Semin Cancer Biol; 2013 Jun; 23(3):183-9. PubMed ID: 23410637
[TBL] [Abstract][Full Text] [Related]
6. The mechanism of action of BCG therapy for bladder cancer--a current perspective.
Redelman-Sidi G; Glickman MS; Bochner BH
Nat Rev Urol; 2014 Mar; 11(3):153-62. PubMed ID: 24492433
[TBL] [Abstract][Full Text] [Related]
7. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
[TBL] [Abstract][Full Text] [Related]
8. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.
Saban MR; O'Donnell MA; Hurst RE; Wu XR; Simpson C; Dozmorov I; Davis C; Saban R
BMC Immunol; 2008 Feb; 9():4. PubMed ID: 18267009
[TBL] [Abstract][Full Text] [Related]
9. Role of neutrophils in BCG immunotherapy for bladder cancer.
Simons MP; O'Donnell MA; Griffith TS
Urol Oncol; 2008; 26(4):341-5. PubMed ID: 18593617
[TBL] [Abstract][Full Text] [Related]
10. Cytological, histological, and clinical correlations in intravesical Bacillus Calmette-Guerin immunotherapy.
Bhan R; Pisharodi LR; Gudlaugsson E; Bedrossian C
Ann Diagn Pathol; 1998 Feb; 2(1):55-60. PubMed ID: 9845722
[TBL] [Abstract][Full Text] [Related]
11. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
12. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
Begnini KR; Buss JH; Collares T; Seixas FK
Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Miyazaki J; Onozawa M; Takaoka E; Yano I
Int J Urol; 2018 May; 25(5):405-413. PubMed ID: 29506322
[TBL] [Abstract][Full Text] [Related]
15. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine.
Kawai K; Miyazaki J; Joraku A; Nishiyama H; Akaza H
Cancer Sci; 2013 Jan; 104(1):22-7. PubMed ID: 23181987
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
[TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
18. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
[TBL] [Abstract][Full Text] [Related]
20. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
